Related Experiment Video

Updated: May 21, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Does IgA antibody against β2 glycoprotein I increase cardiovascular risk in hemodialysis patients?

Rajesh K Patel, Roopen Arya

    Kidney International
    |June 1, 2012
    PubMed

    Insights

    Cardiovascular disease is a major risk for hemodialysis patients. A study links IgA antibodies against β2 glycoprotein I to increased cardiovascular events in these patients.

    Area of Science:

    • Nephrology
    • Cardiology
    • Immunology

    Background:

    • Cardiovascular disease (CVD) is the leading cause of death in patients undergoing hemodialysis.
    • These patients face traditional cardiovascular risk factors alongside uremia and chronic inflammation, contributing to excess CVD mortality.
    • Specific immune factors may also play a role in CVD among this population.

    Purpose of the Study:

    • To investigate the association between IgA antibodies against β2 glycoprotein I and cardiovascular events in hemodialysis patients.
    • To explore novel risk factors for cardiovascular mortality in chronic kidney disease (CKD) patients on dialysis.

    Main Methods:

    • The study by Serrano et al. examined IgA antibody levels against β2 glycoprotein I.
    • Patient data included those undergoing renal dialysis.
    • Cardiovascular events were tracked in the study cohort.

    Main Results:

    • A significant link was identified between IgA antibodies targeting β2 glycoprotein I and the occurrence of cardiovascular events.
    • This suggests a potential role for this specific antibody in driving CVD in dialysis patients.

    Conclusions:

    • IgA antibodies against β2 glycoprotein I may serve as a biomarker or contributing factor to cardiovascular events in hemodialysis patients.
    • Further research is warranted to elucidate the mechanisms and clinical implications of this finding for managing CVD risk in CKD.

    More Related Videos

    Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro14:18

    Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

    Published on: October 13, 2023

    Related Concept Videos

    Hemodialysis II: Procedure and Complications01:24

    Hemodialysis II: Procedure and Complications

    DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
    Diabetic Nephropathy01:28

    Diabetic Nephropathy

    Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
    Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

    Acute Kidney Injury IV: Diagnostic Studies and Prevention

    Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
    Chronic Kidney Disease II: Clinical Manifestations01:24

    Chronic Kidney Disease II: Clinical Manifestations

    Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Chronic Kidney Disease III: Interprofessional Care01:28

    Chronic Kidney Disease III: Interprofessional Care

    Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...